| Name | Title | Contact Details |
|---|
Fette America is a Rockaway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.
Caliper Life Sciences is a Hopkinton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We founded Cedilla at a time of fundamental and rapidly growing insight into the mechanisms underlying protein stability. Small molecules that degrade or stablize target proteins are precedented, but have been discovered serendipitously. Cedilla is taking an integrated approach to discover new drugs with this mode of action. Our present focus is to develop novel medicines in oncology, but this approach will also be applicable to other fields, including central nervous system disorders and genetic diseases. Cedilla launched with $56.2 million in Series A funding from Third Rock Ventures.
NKMax America is harnessing the power of the body`s immune system through the development of unique Natural Killer (NK) cell therapies. NK cell adoptive immunotherapy enhances a patient`s ability to destroy abnormal cells.